Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carbon C 14-AC0010

A radioconjugate composed of AC0010, an orally available, third generation, selective inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), including the second-site resistance mutation T790M, that is labeled with the radioisotope carbon C 14, with potential use in evaluating the pharmacokinetic profile of AC0010. Upon administration, the AC0010 moiety specifically and irreversibly binds to and inhibits the activity of mutant forms of EGFR.Labeling of AC0010 with the radioactive tracer carbon C 14 allows for the evaluation of AC0010's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[14C] AC0010
14C-AC0010
14C-labeled AC0010
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search